ANVS Stock Overview
A clinical stage drug platform company, develops drugs to treat neurodegeneration.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Annovis Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.47 |
| 52 Week High | US$22.49 |
| 52 Week Low | US$4.53 |
| Beta | 1.73 |
| 11 Month Change | -12.59% |
| 3 Month Change | 52.34% |
| 1 Year Change | -11.40% |
| 33 Year Change | -76.77% |
| 5 Year Change | n/a |
| Change since IPO | -11.68% |
Recent News & Updates
Recent updates
Annovis Bio Rallies On Missed ITT Parkinson's Study Endpoints
Jul 08Annovis: Strong Sell Reiteration Prior To Phase 3 Data In Parkinson's Disease
Jun 30Annovis Bio: Alzheimer's Phase 2/3 Topline Readout Puts Future For Buntanetap Into Question
May 02Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects
Feb 12Annovis And Alzheimer's Disease: The Best-Laid Plans
Jan 30Annovis Bio: Buntanetap Likely To Disappoint In The Upcoming AD And PD Clinical Trials
Jan 20Annovis: Due Diligence Prior To Parkinson's And Alzheimer's Readouts
Oct 16Annovis Bio (NYSE:ANVS) Will Have To Spend Its Cash Wisely
Sep 08
Annovis Bio: End Of 2023 Parkinson's Data Could Shift Momentum
Jun 28Annovis wins EU nod to expand late-stage trial for Parkinson's candidate
Feb 08We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth
Jan 28Annovis gains amid ‘strong’ enrollment in late-stage trial Parkinson's drug
Jan 25Annovis: Late-Stage Parkinson's Disease Trial Advancement Makes It Worth A Look
Oct 06We're Hopeful That Annovis Bio (NYSE:ANVS) Will Use Its Cash Wisely
Sep 15Annovis Bio announces publication of three U.S. patents covering lead asset
Sep 13Annovis Bio gains as dosing begins in late-stage trial for Parkinson’s candidate
Aug 24Annovis Bio wins FDA nod to begin late-stage study for Parkinson's candidate
Jul 07Annovis Bio (NYSE:ANVS) Is In A Good Position To Deliver On Growth Plans
May 14We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth
Feb 10Here's Why We're Not Too Worried About Annovis Bio's (NYSEMKT:ANVS) Cash Burn Situation
Apr 16Do Institutions Own Annovis Bio, Inc. (NYSEMKT:ANVS) Shares?
Feb 23We Think Annovis Bio (NYSEMKT:ANVS) Can Afford To Drive Business Growth
Jan 01
Shareholder Returns
| ANVS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.6% | -1.3% | 1.2% |
| 1Y | -11.4% | 23.2% | 30.2% |
Return vs Industry: ANVS underperformed the US Biotechs industry which returned 23.2% over the past year.
Return vs Market: ANVS underperformed the US Market which returned 30.2% over the past year.
Price Volatility
| ANVS volatility | |
|---|---|
| ANVS Average Weekly Movement | 29.1% |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ANVS's share price has been volatile over the past 3 months.
Volatility Over Time: ANVS's weekly volatility has increased from 23% to 29% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 11 | Maria Maccecchini | www.annovisbio.com |
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company’s lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer’s disease (AD), Parkinson’s disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia.
Annovis Bio, Inc. Fundamentals Summary
| ANVS fundamental statistics | |
|---|---|
| Market cap | US$110.57m |
| Earnings (TTM) | -US$43.02m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.6x
P/E RatioIs ANVS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANVS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$43.02m |
| Earnings | -US$43.02m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.30 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ANVS perform over the long term?
See historical performance and comparison